Abstract
Drug-induced vessel vasculitis is a rare complication of chemotherapy. In particular, few reports have investigated drug-induced large vessel vasculitis. We herein report the case of a 57-year-old woman with advanced lung adenocarcinoma who developed perinuclear anti-neutrophil cytoplastic antibodies (p-ANCA)-positive periaortitis induced by bevacizumab combination chemotherapy. With the increasing use of combination therapy with bevacizumab, the incidence of vascular complications will potentially increase. A noninfectious fever occurring during chemotherapy might be a sign of vasculitis; therefore, we must ensure that possible periaortitis is not overlooked.
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / immunology
-
Adenocarcinoma of Lung
-
Antibodies, Antineutrophil Cytoplasmic / adverse effects*
-
Antibodies, Antineutrophil Cytoplasmic / biosynthesis*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Aortitis / diagnosis*
-
Aortitis / drug therapy
-
Aortitis / immunology
-
Bevacizumab
-
Female
-
Humans
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Middle Aged
Substances
-
Antibodies, Antineutrophil Cytoplasmic
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab